Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory, Multiple Myeloma”

1,385 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,385 results

Early research (Phase 1)WithdrawnNCT02658396
What this trial is testing

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma
Dana-Farber Cancer Institute
Testing effectiveness (Phase 2)Study completedNCT01421186
What this trial is testing

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
MorphoSys AG 91
Large-scale testing (Phase 3)Ended earlyNCT01002248
What this trial is testing

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
AEterna Zentaris 135
Early research (Phase 1)Looking for participantsNCT06153251
What this trial is testing

Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 187
Testing effectiveness (Phase 2)Study completedNCT00448201
What this trial is testing

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
UNC Lineberger Comprehensive Cancer Center 71
Testing effectiveness (Phase 2)Active Not RecruitingNCT03145181
What this trial is testing

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 302
Testing effectiveness (Phase 2)Ended earlyNCT02661022
What this trial is testing

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Stemline Therapeutics, Inc. 9
Early research (Phase 1)Study completedNCT04773522
What this trial is testing

JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Pharmaceutical K.K. 15
Early research (Phase 1)Study completedNCT02992483
What this trial is testing

Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Novartis Pharmaceuticals 31
Early research (Phase 1)Not Yet RecruitingNCT05498545
What this trial is testing

Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Second Affiliated Hospital of Xi'an Jiaotong University 34
Early research (Phase 1)Study completedNCT00741377
What this trial is testing

Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

Who this might be right for
Multiple Myeloma Bone Disease
Novartis Pharmaceuticals 28
Not applicableEnded earlyNCT00813501
What this trial is testing

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseInfection+7 more
City of Hope Medical Center 60
Not applicableEnded earlyNCT06068400
What this trial is testing

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Guangzhou Bio-gene Technology Co., Ltd 1
Very early researchLooking for participantsNCT06663046
What this trial is testing

Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma

Who this might be right for
Multiple MyleomaRefractory and Relapsed Multiple Myeloma
Wondercel Biotech (ShenZhen) 30
Early research (Phase 1)Ended earlyNCT03023527
What this trial is testing

Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

Who this might be right for
Multiple Myeloma
PETHEMA Foundation 6
Not applicableStudy completedNCT02555839
What this trial is testing

Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice

Who this might be right for
Multiple Myeloma
Celgene 127
Early research (Phase 1)Ended earlyNCT04178902
What this trial is testing

The Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)Cancer
AbbVie 8
Early research (Phase 1)Study completedNCT00003962
What this trial is testing

Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Early research (Phase 1)Study completedNCT00398515
What this trial is testing

Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Study completedNCT02751255
What this trial is testing

Daratumumab in Combination With ATRA

Who this might be right for
Multiple Myeloma
Amsterdam UMC, location VUmc 60
Load More Results